Omereflux (Omeprazole)

Omeprazole, the active ingredient in Omereflux, is a proton pump inhibitor presented as a strength/form for oral use. It reduces stomach acid production and is used to treat acid‑related conditions in adults and children. GNH USA supplies Omereflux as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Omereflux as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omereflux is a proton pump inhibitor that acts on the gastric acid secretion pathway to manage several acid‑related disorders.

- Gastro‑esophageal reflux disease (GERD): provides symptomatic relief and promotes healing of erosive esophagitis. - Peptic ulcer disease: supports ulcer healing and reduces recurrence risk. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with the condition. - Helicobacter pylori eradication regimens (as part of combination therapy): enhances eradication rates when used with antibiotics. - NSAID‑induced ulcer prevention: lowers the risk of ulcer development in patients requiring long‑term NSAID therapy.

Omereflux may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: loose stools that may resolve with continued therapy. - Nausea: occasional feeling of queasiness. - Abdominal pain: cramp‑like discomfort in the stomach area. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis presenting with watery diarrhea. - Hypomagnesemia: low serum magnesium levels that may cause muscle cramps or cardiac arrhythmia. - Acute interstitial nephritis: kidney inflammation presenting with reduced urine output. - Stevens‑Johnson syndrome: severe skin reaction with blistering and mucosal involvement. - Liver enzyme elevation: increased ALT/AST indicating potential hepatic stress. - Bone fracture risk: potential reduction in calcium absorption with long‑term use.

When prescribing Omereflux, clinicians should consider several safety aspects.

- Assess renal function: dose adjustment may be needed in severe impairment. - Review concomitant medications: potential for drug‑drug interactions. - Monitor for infection: prolonged acid suppression can increase risk of gastrointestinal infections. - Evaluate bone health: long‑term therapy may affect calcium absorption. - Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Omereflux can affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, may increase cardiovascular risk. - Atazanavir: decreased antiviral absorption, compromising HIV therapy. - Methotrexate (high dose): increased systemic exposure, risk of toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of INR, require more frequent monitoring. - Digoxin: slight increase in serum levels, watch for toxicity signs. - Diazepam: enhanced sedative effect, monitor patient response.